Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients

Andrea Haddad(The University of Texas MD Anderson Cancer Center), Issam Raad(Missouri Department of Agriculture), Mohamed Ben Moussa(The University of Texas MD Anderson Cancer Center), Ray Hachem(The University of Texas MD Anderson Cancer Center), Ying Jiang(The University of Texas MD Anderson Cancer Center), Anne‐Marie Chaftari(The University of Texas MD Anderson Cancer Center), Hiba Dagher(The University of Texas MD Anderson Cancer Center), Patrick Chaftari(The University of Texas MD Anderson Cancer Center)
Cancers
March 5, 2024
Cited by 9


Related Papers